Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

• Main Authors: Daniel F. Hoft, Azra Blazevic, Asmir Selimovic, Aldin Turan, Jan Tennant, Getahun Abate, John Fulkerson, Daniel E. Zak, Robert Walker, Bruce McClain, Jerry Sadoff, Judy Scott, Barbara Shepherd, Jasur Ishmukhamedov, David A. Hokey, Veerabadran Dheenadhayalan, Smitha Shankar, Lynn Amon, Garnet Navarro, Rebecca Podyminogin, Alan Aderem, Lew Barker, Michael Brennan, Robert S. Wallis, Anne A. Gershon, Michael D. Gershon, Sharon Steinberg
• Format: Article
• Language: English
• Published: Elsevier 2016-05-01
• Series: EBioMedicine
• Subjects: Tuberculosis; Recombinant BCG; Herpes zoster; Transcriptomes; Functional T cell assays
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352396416301451

Background: We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. Methods: This was a randomized, double-blind, dose-escalation trial in HIV-negative, healthy adult, BCG-naïve volunteers, negative for prior exposure to Mtb, at one US clinical site. Volunteers were randomized 2:1 at each dose level to receive a single intradermal dose of AERAS-422 (>105–< 106 CFU = low dose, ≥106– < 107 CFU = high dose) or non-recombinant Tice BCG (1–8 × 105 CFU). Randomization used an independently prepared randomly generated sequence of treatment assignments. The primary and secondary outcomes were safety and immunogenicity, respectively, assessed in all participants through 182 days post-vaccination. ClinicalTrials.gov registration number: NCT01340820. Findings: Between Nov 2010 and Aug 2011, 24 volunteers were enrolled (AERAS-422 high dose, n = 8; AERAS-422 low dose, n = 8; Tice BCG, n = 8); all were included in the safety and immunogenicity analyses. All 24 subjects had at least one adverse event, primarily expected local reactions. High dose AERAS-422 vaccination induced Ag85A- and Ag85B-specific lymphoproliferative responses and marked anti-mycobacterial activity in a whole blood bactericidal activity culture assay (WBA), but was associated with varicella zoster virus (VZV) reactivation in two vaccinees. These volunteers displayed high BCG-specific IFN-γ responses pre- and post-vaccination possibly predisposing them to autocrine/paracrine negative regulation of immune control of latent VZV. A systems biology transcriptomal approach identified positive correlations between post-vaccination T cell expression modules and WBA, and negative correlations between post-vaccination monocyte expression modules and WBA. The expression of one key macrophage marker (F4/80) was constitutively elevated in the two volunteers with zoster. Interpretation: The unexpected development of VZV in two of eight healthy adult vaccine recipients resulted in discontinuation of AERAS-422 vaccine development. Immunological and transcriptomal data identified correlations with the development of TB immunity and VZV that require further investigation. Funding: Aeras, FDA, Bill and Melinda Gates Foundation.